Clinical Trial Update: INdividualized ITI Based on Fviii(ATE) Protection by VWF [Phase 4]

View source ↗

Summary

Phase 4 trial update for individualized ITI based on FVIII protection by von Willebrand factor in Hemophilia A patients with inhibitors; trial terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia
• Hemophilia with Inhibitors

Snippet

Sponsor: University of California, Davis | Conditions: Hemophilia A With Inhibitor, Hemophilia A | Phase 4 | Status: TERMINATED | Results posted: 2020-05-29